Karla A. Fenton

TL;DR: It is shown that lipid-nanoparticle-encapsulated short interfering RNAs (siRNAs) rapidly adapted to target the Makona outbreak strain of Ebola virus are able to protect 100% of rhesus monkeys against lethal challenge when treatment was initiated at 3 days after exposure while animals were viraemic and clinically ill.

TL;DR: It is reported that African green monkeys infected with the SARS-CoV-2 virus develop disease symptoms that closely resemble those seen in infected humans, making this animal model a useful surrogate to investigate immune responses to coronavirus infection.

TL;DR: Results represent the successful therapeutic in vivo efficacy by an investigational drug against Nipah virus in a nonhuman primate and highlight the potential impact that a monoclonal antibody can have on a highly pathogenic zoonotic human disease.

TL;DR: The EILV platform represents the first structurally native application of an insect-specific virus in preclinical vaccine development and highlights the potential application of such viruses in vaccinology.

TL;DR: Investigating pathogenic differences between strains of NiV suggests that postexposure treatments may need to be NiV strain specific for optimal efficacy and shows that NiVB is more pathogenic in AGMs under identical experimental conditions.